Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $85.65, for a total value of $53,017.35. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,428,912.10. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Down 1.9%

Edwards Lifesciences stock opened at $84.18 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a market cap of $48.47 billion, a PE ratio of 48.38, a price-to-earnings-growth ratio of 2.25 and a beta of 0.87. The stock’s 50 day moving average price is $88.74 and its 200 day moving average price is $86.17.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the prior year, the business posted $0.67 earnings per share. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its holdings in shares of Edwards Lifesciences by 11.7% during the third quarter. GAMMA Investing LLC now owns 12,599 shares of the medical research company’s stock valued at $1,088,000 after purchasing an additional 1,318 shares during the last quarter. CoreCap Advisors LLC raised its stake in shares of Edwards Lifesciences by 352.7% during the third quarter. CoreCap Advisors LLC now owns 1,177 shares of the medical research company’s stock valued at $102,000 after purchasing an additional 917 shares in the last quarter. YHB Investment Advisors Inc. acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $215,000. Apella Capital LLC boosted its holdings in shares of Edwards Lifesciences by 5.2% in the third quarter. Apella Capital LLC now owns 9,866 shares of the medical research company’s stock valued at $846,000 after acquiring an additional 486 shares in the last quarter. Finally, Plan A Wealth LLC boosted its holdings in shares of Edwards Lifesciences by 3.0% in the third quarter. Plan A Wealth LLC now owns 5,460 shares of the medical research company’s stock valued at $471,000 after acquiring an additional 158 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Barclays initiated coverage with an Overweight rating, also reported as a Strong-Buy recommendation. The call provides fresh bullish support for Edwards’ structural-heart-device business and could help offset recent investor caution. Barclays initiates coverage of Edwards Lifesciences with overweight rating
• Neutral Sentiment: The next major catalyst is the third-quarter earnings report. Edwards plans to release results after the market closes on November 4, 2026, followed by a conference call. Investors may remain cautious while awaiting updated procedure volumes, revenue growth and guidance. Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
• Negative Sentiment: Insider selling is adding to the pressure. Vice President Daniel Lippis sold 619 shares worth approximately $53,000 under a pre-arranged Rule 10b5-1 trading plan. Broader data cited in the report show 24 insider sales and no purchases over the past six months, which may reinforce concerns about near-term sentiment, although planned sales are not necessarily a signal of deteriorating fundamentals. Edwards Lifesciences insider transaction filing
• Negative Sentiment: Investors may be taking profits ahead of the earnings and November 2 investor event. A recent analyst shift to Hold also weighed on sentiment. However, there was no clearly negative company update; Edwards recently announced FDA approval for its AUTUS pediatric pulmonary valve.

Analysts Set New Price Targets

A number of research firms have recently commented on EW. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Piper Sandler restated an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. JPMorgan Chase & Co. upped their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Royal Bank Of Canada upped their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, BTIG Research reissued a “buy” rating and issued a $110.00 price objective on shares of Edwards Lifesciences in a research report on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.